BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
1 clinical trials · Condition
◉ Watch BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia
| Record | Firm | Date |
|---|---|---|
| Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies (NCT07523555) | Beijing Biotech | 2026-03-02 |
Track BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia automatically
Every clearance here is in the API, with alerts when new ones post.